RMD250117P170000
- 1.03
- 0.000.00%
ResMed Newsroom
Is There An Opportunity With ResMed Inc.'s (NYSE:RMD) 31% Undervaluation?
This AppLovin Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
ResMed Analyst Ratings
Piper Sandler Initiates ResMed(RMD.US) With Hold Rating, Announces Target Price $252
Balanced Outlook on ResMed: Strong Execution and Innovations Offset by Valuation Concerns and Market Challenges
Express News | Resmed Inc : Piper Sandler Initiates Coverage With Neutral Rating; Target Price $252
ResMed to Report Second Quarter Fiscal 2025 Earnings on January 30, 2025
Express News | Resmed to Report Second Quarter Fiscal 2025 Earnings on January 30, 2025
3 S&P 500 Earnings Growth Stocks to Buy in 2025: CMG, RMD, NOW
HOLX Stock Gains Following the Acquisition of Gynesonics
ResMed Announces Participation in the 43rd Annual J.P. Morgan Healthcare Conference
Healthcare Sector's 2024 Gainers and Losers: Intuitive Surgical, Boston Scientific Tops Chart
Fluctuations are expected to continue in the early days of Trump's presidency, with Citigroup favoring Medical, Financial, and other defensive Industries.
In the market volatility and uncertainty following Trump's inauguration, defensive industries such as Medical Care and finance are favored in the model portfolio created by Citigroup strategists.
ResMed Inc. Reports Change in Beneficial Ownership
ResMed Gains 37.8% in a Year: What's Driving the Stock?
Resmed Chief Legal Officer Sells Shares
Resmed Inc Adjusts Securities Amid Market Dynamics
ResMed Inc.'s (NYSE:RMD) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?
Will ResMed (RMD) Beat Estimates Again in Its Next Earnings Report?
CICC Initiates ResMed at Outperform With $295 Price Target